论文部分内容阅读
近年来,在世界范围内肾细胞癌(renal cell carcinoma,RCC)的发生率逐年上升。约20%的肾癌患者在疾病诊断时已经发生肿瘤的进展转移,而且近30%的局限性肾癌患者在肿瘤切除后会发生复发转移。受体酪氨酸激酶抑制剂舒尼替尼(Sunitinib,Sutent~被作为进展性肾癌患者的一线治疗方案。但是10%~20%的进展性肾癌患者在初次治疗时就对舒尼替尼先天耐药,其余的患者往往在接受舒尼替尼治疗6至15个月后出现耐药和疾病进展,这些现状使得舒尼替尼并不能有效
In recent years, the incidence of renal cell carcinoma (RCC) in the world has been increasing year by year. Approximately 20% of patients with renal cell carcinoma have undergone tumor metastasis at the time of diagnosis, and nearly 30% of patients with localized renal cell carcinoma relapse and metastasis after tumor resection. Receptor tyrosine kinase inhibitor Sunitinib (Sutent ~ was used as a first-line treatment of patients with advanced renal cell carcinoma, but 10% to 20% of patients with advanced renal cell carcinoma in the initial treatment of Sunitin TINTIN is congenital drug resistant, and the remaining patients often develop resistance and disease progression 6 to 15 months after sunitinib treatment, which renders sunitinib ineffective